Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis (ONICO)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Pierre Fabre Dermo Cosmetique.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Pierre Fabre Dermo Cosmetique
Collaborator:
Quanta Medical
Information provided by:
Pierre Fabre Dermo Cosmetique
ClinicalTrials.gov Identifier:
NCT01014637
First received: November 16, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate and compare the efficacy of the sequential association RV4104A ointment followed by ciclopiroxolamine 1% cream and ciclopirox 8% film-forming solution versus amorolfine 5% nail lacquer alone in the treatment of patients with dermatophytic onychomycosis (toenail) without matrix involvement.
| Condition | Intervention | Phase |
|---|---|---|
|
Onychomycosis |
Drug: Amorolfine (Antifungal) Drug: RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement |
Resource links provided by NLM:
Drug Information available for:
Miconazole nitrate
Miconazole
Clotrimazole
Ciclopirox
Ciclopirox olamine
U.S. FDA Resources
Further study details as provided by Pierre Fabre Dermo Cosmetique:
Primary Outcome Measures:
- To evaluate and compare the efficacy of the sequential association RV4104A ointment-ciclopiroxolamine 1% cream-ciclopirox 8% film-forming solution versus amorolfine 5% nail lacquer alone in dermatophytic onychomycosis (toenail) without matrix involvement [ Time Frame: Day 336 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To evaluate and compare the local tolerability of the sequential association RV4104A-ciclopiroxolamine-ciclopirox versus amorolfine 5% alone in the treatment dermatophytic onychomycosis (toenail) without matrix involvement [ Time Frame: Day 21, Day 77, Day 156, Day 262 ] [ Designated as safety issue: Yes ]
- To evaluate and compare the cost-effectiveness of the sequential association RV4104A ointment-ciclopiroxolamine 1% cream-ciclopirox 8% film-forming solution vs amorolfine 5% alone in the treatment of dermatophytic onychomycosis without matrix involvement [ Time Frame: Day 336 ] [ Designated as safety issue: No ]
- To evaluate and compare the clinical cure of the sequential association RV4104A ointment-ciclopiroxolamine-ciclopirox 8 versus amorolfine alone in the treatment dermatophytic onychomycosis (toenail) without matrix involvement [ Time Frame: Day 77, Day 168, Day 252 ] [ Designated as safety issue: No ]
- Averse Events Reporting [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 260 |
| Study Start Date: | August 2009 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Amorolfine 5% |
Drug: Amorolfine (Antifungal)
Treatment with Amorolfine for 36 weeks
Other Name: Loceryl
|
| Experimental: RV4104A-cylcopiroxolamine-ciclopirox |
Drug: RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of distal-lateral or lateral subungual onychomycosis of one great toenail (the target nail) without matrix involvement
- Target nail plate showing between 25% and 60% of clinically infected area
- Patient must have at least 2 mm of unaffected proximal target nail area
- Target nail infection due exclusively to a dermatophyte (from positive fungal culture as reported by the central mycological laboratory)
- Female patient of childbearing potential must use an efficient contraceptive method for at least 2 months prior to screening visit
- Female patient of childbearing potential must have a negative urinary pregnancy test at the screening visit
Exclusion Criteria:
- Patient with more than 3 affected nails
- Patient with onychomycosis with matrix involvement
- Patient with psoriasis, lichen planus or other abnormalities that could result in clinically abnormal toenail(s)
- Patient with moccasin-type tinea pedis
- Patient who has received systemic antifungal therapy or any topical antifungal therapy applied to the toenails within 3 months prior to screening visit
- Patient with known hypersensitivity to investigational products' ingredient(s)
- Patient who is currently participating or who has participated in another clinical study within 4 weeks prior to screening visit
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01014637
Contacts
| Contact: Jean-Jacques VOISARD, MD | +33 5 63 58 88 00 | jean.jacques.voisard@pierre-fabre.com |
| Contact: Héla COUBETERGUES | + 33 5 61 73 73 38 | hela.coubetergues@pierre-fabre.com |
Locations
| France | |
| Cabinet Médical | Recruiting |
| Argenteuil, France, 95100 | |
| Principal Investigator: Yves LE CORRE, MD | |
| Cabinet Médical | Recruiting |
| Brest, France, 29200 | |
| Principal Investigator: Monique CHASSAIN LE LAY, MD | |
| Cabinet Medical | Recruiting |
| Cholet, France, 49300 | |
| Principal Investigator: Jean-Michel DEBARRE, MD | |
| Cabinet Médical | Recruiting |
| Martigues, France, 13500 | |
| Principal Investigator: Mireille RUER-MULLARD, MD | |
| Cabinet Médical | Recruiting |
| Nice, France, 06000 | |
| Principal Investigator: Gilles ROSTAIN, MD | |
| Hopital Purpan | Not yet recruiting |
| Toulouse, France | |
| Principal Investigator: Carle PAUL, Professor | |
| Cabinet Médical | Recruiting |
| Toulouse, France, 31000 | |
| Principal Investigator: Didier COUSTOU, MD | |
Sponsors and Collaborators
Pierre Fabre Dermo Cosmetique
Quanta Medical
Investigators
| Principal Investigator: | Carle PAUL, Professor | Hopital Purpan |
More Information
No publications provided
| Responsible Party: | Anne-Marie Schmitt, MD, Pierre Fabre Dermo Cosmetiques |
| ClinicalTrials.gov Identifier: | NCT01014637 History of Changes |
| Other Study ID Numbers: | RV4104A 2008 548 |
| Study First Received: | November 16, 2009 |
| Last Updated: | November 16, 2009 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Tunisia: Ministry of Public Health |
Keywords provided by Pierre Fabre Dermo Cosmetique:
|
Dermatomycoses Infection Mycoses |
Nail diseases Ski diseases Skin diseases/infectious |
Additional relevant MeSH terms:
|
Onychomycosis Tinea Dermatomycoses Skin Diseases, Infectious Infection Mycoses Nail Diseases Skin Diseases Antifungal Agents Clotrimazole Miconazole |
Amorolfine Ciclopirox Keratolytic Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Anti-Infective Agents, Local 14-alpha Demethylase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Dermatologic Agents |
ClinicalTrials.gov processed this record on May 16, 2013